VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with central nervous system (CNS) diseases. The company's lead product candidate, AV-101, which is in Phase IIa development as a augmentation option for adult patients suffering from treatment-resistant major depressive disorder (TRD). It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary small molecule new chemical entities (NCEs) for its internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and/or liver cells derived from hPSCs. In addition, the company offers CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. It has strategic collaborations with University Health Network, the McEwen Centre for Regenerative Medicine, and the Centre for the Commercialization of Regenerative Medicine for stem cell technology research, development, and cell production; and Norac Pharma, Pharmatek, and Synterys, Inc. to design, produce, and analyze AV-101 clinical trial materials and potential drug rescue NCEs. The company also has strategic relationships with Pharmaceutical Product Development, LLC; Cato Research, Ltd.; and Massachusetts General Hospital Clinical Trials Network and Institute for regulatory expertise and clinical development support. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.